Histones can mediate the binding of DNA and anti-DNA to the glomerular basement membrane (GBM). In ELISA histone/DNA/anti-DNA complexes are able to bind to heparan sulfate (HS), an intrinsic constituent of the GBM. We questioned whether histone containing immune complexes are able to bind to the GBM, and if so, whether the ligand in the GBM is HS. Monoclonal antibodies (mAbs) complexed to nucleosomal antigens and noncomplexed mAbs were isolated from culture supernatants of four IgG anti-nuclear mAbs. All noncomplexed mAbs showed strong anti-nucleosome reactivity in ELISA. One of them showed in addition anti-DNA reactivity in noncomplexed form. The other three mAbs only showed anti-DNA reactivity when they were complexed to nucleosomal antigens. After renal perfusion a fine granular binding of complexed mAbs to the glomerular capillary wall and activation of complement was observed in immunofluorescence, whereas noncomplexed mAbs did not bind. Immuno-electron microscopy showed binding of complexes to the whole width of the GBM. When HS in the GBM was removed by renal heparinase perfusion the binding of complexed mAb decreased, but did not disappear completely.
ease characterized by the occurrence of numerous auto-antibodies directed primarily against nuclear antigens. Antibodies against double-stranded DNA (dsDNA) are regarded as highly specific for the disease (1) . Nephritis is one of the most serious manifestations of the disease. Since nephritis is associated with a rise in titer of especially high avidity IgG anti-dsDNA and a depression of serum complement, it is generally assumed that these antibodies are involved in the pathogenesis of lupus ne-*phritis and that they cause complement activation (2-4). Moreover, enrichment of these antibodies in renal and glomerular eluates of SLE patients and lupus mice has been found, sustaining the nephritogenic properties of these antibodies (5-7). How these antibodies bind in the glomerulus, however, is still unclear. The classical hypothesis that anti-DNA is deposited in the glomerular basement membrane (GBM) as DNA/anti-DNA immune complexes has been subject of much controversy (8) . For instance, when artificially prepared DNA/anti-DNA immune complexes are injected in experimental animals, they show no affinity for the GBM, but instead are rapidly cleared by the liver (9) (10) (11) . Indeed, it is not very likely that the negatively charged DNA in anti-DNA/DNA complexes would easily de- posit in the negatively charged GBM (12). This controversy led Schmiedeke et al. ( 13) to the idea that binding of histones, which are highly positively charged DNA binding proteins might mediate the binding of DNA and anti-DNA. At the same time, analyzing the cross-reactivity of anti-DNA antibodies with heparan sulfate (HS), an intrinsic constituent of the GBM, we found that this cross-reactivity was due to histone/DNA containing immune complexes (14) . The histone part in these complexes was responsible for the binding to HS. Furthermore, when we perfused subsequent histones, DNA and anti-DNA in a rat kidney, we observed a strong fine granular binding of antibodies to the capillary wall in immunofluorescence (IF), whereas after perfusion of DNA and anti-DNA, the binding was much less and restricted to the mesangium (15) . The concept that histones may play a role in the initiation of lupus nephritis (reviewed recently in reference 16) was further substantiated by the finding of histone deposits in human and murine SLE nephritis (17, 18) .
We realized however, that subsequent perfusion of purified histones, DNA and anti-DNA is a rather artificial system. It is not likely for histones and DNA to exist as separate entities in vivo. Indeed, in the circulation DNA is present bound to histones forming oligonucleosomal complexes (19, 20) . When such nucleosomal material is released in the circulation of SLE patients, it is very likely that immune complexes are formed with anti-nuclear antibodies with specificity for either histones, nucleosomes or DNA. As we described before (14, 21) a similar complex formation occurs in supernatants of hybridomas secreting anti-nuclear antibodies. In these supernatants mAbs can be found complexed with nucleosomal antigens released from dying cells. That is why we chose to isolate immune complexes from such culture supernatants, to find out which characteristics of these immune complexes are associated with binding capacity in the GBM.
Methods
Production of monoclonal antibodies mAbs were obtained by fusion of spleen cells from mice with spontaneous ([NZB X W]Fl, MRL/Mp/Ipr/Ipr) or experimentally induced (parental-Fl chronic Graft Versus Host disease) SLE and screened for the presence of anti-dsDNA reactivity in ELISA or Farr assay as described previously (22) and new culture supernatants were prepared from which antibodies were purified. For the studies described in this paper, mAbs were selected which showed reactivity with HS in crude culture supernatants, since this reactivity is due to mAbs complexed to nucleosomal material (histones and DNA) as described previously ( 14) . All selected mAbs belong to the IgG2a subclass.
Preparation of immune-complexed and pure mAbs Hybridomas were grown in serum free conditions (IMDM; GIBCO-BRL, Paisley, UK) supplemented with serum-free medium supplement, SF1 (Costar, Cambridge, MA) 2% vol/vol. Three purification procedures were used.
Procedure I (physiological conditions). Culture supernatants were applied to a protein-A Sepharose column (Pharmacia, Uppsala, Sweden) equilibrated with phosphate buffered saline (PBS).
Procedure II (high salt conditions). NaCl, glycine and NaOH were added to culture supernatants to a final concentration of 3 M NaCl, 1.5 M glycine, pH 8.9, before applying to a protein-A Sepharose column which was equilibrated with a 3 M NaCl, 1.5 M glycine, pH 8.9 buffer.
Procedure III (DNase and high salt conditions). In this procedure the purification under high salt conditions was preceded by a DNase treatment. The culture supernatants were first treated with DNaseI (Boehringer Mannheim, Mannheim, Germany) with a final concentration of 40 jug/ml in the presence of 10 mM MgCl2. After 1 h incubation at 37°C the reaction was quenched with EDTA (Merck, Darmstadt, Germany) with a final concentration of 15 mM.
After each of these three different purification procedures immunoglobulins bound to the protein A column were eluted with a solution of 0.1 M citric acid, pH 2.6. The eluate was immediately brought to pH 7.4, dialyzed against PBS and stored at -20°C.
Using the third procedure, noncomplexed mAbs were obtained except for mAb No. 34. For this mAb still a fraction of the antibodies was complexed to nucleosomal antigens. The complexed and noncomplexed antibodies were separated with the use of a DNA-cellulose column (P-L Biochemicals, Inc., Milwaukee, WI), which was equilibrated with PBS. Complexed antibodies retained on the column, whereas pure, noncomplexed antibodies were obtained in the column effluent. The immunoglobulin (Ig) concentration was determined in an ELISA, for which Nunc-immuno plates (Maxisorp F96; GIBCO BRL)
were coated overnight at 40C with goat anti-mouse Ig (Sigma Chemical Co., St. Louis, MO) diluted 1:80 in PBS, 100 jil per well. Plates were washed five times with PBS containing 0.05% (vol/vol) Tween 20 and blocked with PBS containing 1% wt/vol gelatin for 2 h at 37°C. Samples were serially diluted in PBS/1% gelatin and incubated for 1 h at 37°C. Next, plates were washed again and 100 ,ul of peroxidase-conjugated goat anti-mouse IgG2a diluted 1:750 (Southern Biotechnology Assoc. Inc., Birmingham, AL) in PBS/1% gelatin were added per well. After 1 h of incubation at 37°C, the plates were washed. A freshly prepared substrate solution of 0.8 mg/ml 5' aminosalicylic acid dissolved in 50 mM phosphate buffer, pH 6.0, supplemented with 0.8 .ld/ml 30% vol/ vol H202 was added to each well. After 30 min the OD at 450 nm was measured. An IgG2a myeloma protein (RPC 5; Cappel, Organon Technika NV, Turnhout, Belgium) was used as standard.
Tests for antigen reactivity ofpurified and complexed anti-nuclear mAbs Anti-dsDNA assays. Anti-dsDNA activity was determined in the Farr assay and in an anti-dsDNA ELISA. The Farr assay was performed as described previously (23) . In the anti-dsDNA ELISA photobiotinylated PUC9 plasmid DNA was used (24, 25) . Briefly, plates (Maxisorb F96, GIBCO-BRL) used for the ELISA were coated overnight with streptavidin (Sigma Chemical Co.) diluted in distilled water (150 Hg in 150 pl/well) at 4°C. The plates were washed three times in PBS, containing 0.05% Tween 20 and three times with distilled water. Next, the plates were coated overnight with photobiotinylated DNA (1 jig/ml in PBS, 4°C, 150 /l/well). The plates were washed again and blocked for 2 h at room temperature with PBS containing 10% (vol/vol) normal goat serum (NGS). The use of this blocking agent did not influence the binding of the different mAb preparations when compared to gelatin or BSA, excluding interference by putatively present nucleosomes or nucleohistone. This was further substantiated by the fact that mAbs with a specificity restricted to nucleosomes did not bind to plates coated with the batch of NGS used for blocking. Samples were serially diluted in PBS, 0.05% Tween 20, containing 10% NGS and incubated for 2 h at room temperature.
Next, the plates were washed again and 100 /lA of peroxidase labeled rat mAb anti-mouse Ig (CLB-RM-19; CLB, Amsterdam, the Netherlands) diluted 1:1,000 in PBS were added per well. The plates were washed again and developed with 3,5,3 ',5 '-tetramethylbenzidine (Merck), 100 og/ml in 0.11 M sodium acetate, pH 5.5, containing 0.003% H202. By adding 2 M H2SO4, 100 pl/well, color development was stopped after 15 min and OD at 450 nm was measured.
Anti-HS ELISA. HS, purified from bovine kidney, was purchased from Seikagugu Kogyo Ltd (Tokyo, Japan). Photobiotinylation of HS was performed in the same way as described for DNA (25). The concentration of HS was determined by the Farndale assay (26) . The ELISA was performed identically as described for DNA. A mAb against HS (JM 403, described in reference 27) was used as a positive control.
Anti-histone ELISA. A mixture of the five histones (HI, H2a, H2b, H3, and H4, 2.5 ,ug/ml Boehringer Mannheim) in 0.1 M Glycine/NaOH, pH 9, 0.1 M NaCl was coated overnight at 4°C to Nunc-immuno plates. The plates were washed five times with PBS/0.05% Tween Renal perfusion studies Male Wistar rats (150 g) were anesthetized by intraperitoneal administration of 0.15 ml (9 mg) sodium pentobarbital (Narcovet, Apharmo, Arnhem, The Netherlands).
The renal perfusion was performed as described before (15) . After perfusion the perfused kidney was taken out and immediately snap frozen in liquid N2 for immunofluorescence (IF).
In some experiments only a small part of the kidney was taken for IF. The remaining part was perfused with PLP for 10 min and prepared for immuno-electron microscopy (JEM) (for details, see below).
In additional experiments, after placing a ligature around the aorta between the origins of the left and the right renal artery, a 24-gauge catheter was placed in the aorta and the vena cava was not incised. The left kidney was flushed with 0.3 ml 1% (wt/vol) BSA in PBS, followed by perfusion of pure mAb or immune complexes (150-500 jig in 500 Ml), which were allowed to bind for 3 min. After flushing the left kidney again with 0.3 ml PBS-1% BSA, the ligature and catheter were removed to re-establish normal blood flow.
After 15 min the ligature was placed again and an 18-gauge catheter was placed in the aorta and the left kidney was flushed for 3 min with PBS-l% BSA, before it was taken out and snap frozen in liquid N2 or prepared for IEM by PLP perfusion.
Heparinase perfusion
After placing the ligature and insertion of an 18-gauge catheter, the left kidney was flushed with saline for 2 min. Next heparinase III (Sigma Chemical Co.) 60 U in saline containing 1% BSA and 5 mM CaCl2 was perfused at a flow rate of 1 ml/min. The enzyme was allowed to act for 4 min. Next the kidney was flushed with PBS-l% BSA for 3 min. This heparinase perfusion was followed by perfusion of complexed mAbs. The kidney was further processed as described above. To control for nonspecific changes, perfusion was performed with buffer without heparinase and subsequent with complexed mAbs. Experiments were repeated three times with different amounts of perfused complexed a rabbit anti histone polyclonal antiserum diluted 1:600. This antiserum was prepared as described before (15) . After rinsing with PBS bound rabbit antibodies were visualized using a FITC-labeled mouse antirabbit IgG(H + L) diluted 1:40 (Jackson Laboratories Inc., West Groove, PA). In experiments in which the blood flow was restored after perfusion, sections were also stained with FITC-labeled goat anti-rat C3 diluted 1:40 (Nordic, Tilburg, the Netherlands).
In the experiments in which heparinase was perfused before perfusion of complexed mAbs, sections were stained with a mouse IgM anti-HS-glycosaminoglycan (HS-GAG) side chain mAb (JM 403, described in reference 27) and with a goat anti-human HS-core protein antiserum cross reacting with rat HS-proteoglycan (HSPG, described in reference 29). As secondary antibodies FITC labeled goat anti-mouse IgM (Fc) (Nordic) diluted 1:100 or FITC-labeled rabbit anti-goat Ig (De Beer Med. BV, Hilvarenbeek, the Netherlands) diluted 1:500 were used. The sections were also stained with a rabbit anti-rat (L2) laminin polyclonal antiserum diluted 1:400 and with a goat anti-human collagen IV polyclonal antiserum cross-reacting with rat diluted 1:200, which were both prepared in our laboratory, followed by FITC-labeled mouse anti-rabbit Ig Immuno-electron microscopy. Tissue was prepared for IEM by perfusion of the kidneys during 10 min with a mixture of 0.01 M sodium periodate, 0.075 M lysine HCO, 0.0375 M Na2HPO4 and 2% paraformaldehyde (PLP). Thereafter the kidney was cut into small pieces (5 x 5 X 1 mm) and immersed in PLP for another 3 h. Next, the tissue was washed in PBS for 30 min and cryoprotected by immersion in 80% wt/ vol sucrose in PBS for 1 h, before they were snap frozen in liquid N2.
20-pm sections were incubated with a peroxidase labeled anti- Table I (In vitro reactivity). In Fig. 3 Fig. 4 . In purified form none of the mAb showed any binding. The major determinant for GBM binding was the presence of histones in the complex, irrespective of the amount of DNA present. In fact for mAbs No. 32 and 34 the magnitude of the binding was even larger for preparations obtained after purification under high salt conditions (procedure II, reducing the amount of bound DNA considerably), compared with preparations obtained after purification under physiological conditions (procedure I; not removing the DNA from the nucleosomal particle). This suggests that reduction of the DNA content within the nucleosome enhances the glomerular binding. The involvement of histones in this GBM binding is further substantiated by indirect IF using an anti-histone antiserum showing besides nuclear staining, a fine granular deposition of histones along the capillary wall after perfusion of complexed mAb (Fig.  5 A) , but no capillary wall staining after perfusion of pure noncomplexed mAb (Fig. 5 B) . At the ultrastructural level the Ig binding occurred through the whole width of the GBM, with only very limited binding to the endothelium or the mesangium Figure 7 . Direct immunofluorescence for rat C3 after perfusion with mAb No. 32 complexed to histones, followed by restoration of the blood flow for 15 min. Note deposition of rat C3 in the capillary wall of the glomerulus (A). When pure mAb No. 32 was perfused followed by restoration of the blood flow, there was no deposition of rat complement in the glomerulus (B), only staining of the basal part of the proximal tubular cells, which is normal in rat kidneys (X480). (Fig. 6, A and B) . That this glomerular binding may have pathogenic potential can be derived from the observation that restoration of the renal circulation after perfusion of complexed mAbs leads to C3 deposition along the capillary wall in a pattern identical to that of the Ig deposits (Fig. 7) .
Glomerular binding after perfusion ofnucleosome reconstituted complexes. When purified mAbs were reconstituted with purified nucleosomes, glomerular binding was observed in IF after perfusion, which was comparable with the binding seen after perfusion of complexed antibodies obtained from culture supernatants. A representative example of the observed binding is given in Fig. 8 . When the noncomplexed mAb, used for the reconstitution of these immune complexes, was perfused, no binding was observed, indicating that it was the nucleosome in the complex, which mediated the glomerular binding of the antibodies. In addition perfusion of nucleosomes with a nonrelevant mAb WTI directed against human CD7 did not lead to glomerular antibody binding.
Binding of complexed mAbs after heparinase perfusion. To investigate the significance of GBM-HS in the glomerular binding of complexed mAb, heparinase was perfused before mAb perfusion. After heparinase, staining of the HS-GAG side chain within the GBM had almost disappeared completely, whereas staining of the HSPG-core protein was intact, indicating that the HS-GAG side chain was effectively removed from the core protein by this procedure (Fig. 9) . Staining of other GBM components, like laminin or collagen IV also remained intact (data not shown). If histone-containing immune complexes were perfused after heparinase perfusion, binding of the mAb decreased, but did not disappear totally (Table 11 , Fig. 9 ), suggesting that HS is not the only ligand through which these immune complexes can bind to the GBM as we have already suggested before ( 15) .
Discussion
In previously reported experiments from others (13) and from our laboratories (14, 15, 30) , it was shown that anti-dsDNA antibodies can bind to the GBM via an intermediate bridge of histones and DNA, in which the histone part is responsible for the binding to anionic sites in the GBM (for review see reference 16). Since our previous studies were performed with subsequent separate perfusion of histones, DNA, and purified anti-DNA, we now extend these observations in the present study by using mAb to nucleosomal antigens. These mAbs were se-- Figure 9 . Indirect immunofluorescence of a kidney perfused with heparinase compared with a control perfusion. After control perfusion the staining of HSPG-core protein (A) and HS-GAG side chain (C) is intact. In the kidney perfused with heparinase the staining of the HSPG-core protein is still intact (B), whereas the staining of the HS-GAG side chain has disappeared (D). When mAb No. 32 complexed to histones is perfused after heparinase or a control perfusion, the binding of complexed mAb is decreased in the heparinase perfused kidney (F) as compared with the control perfusion (E) (A-D, x350; E, x400; F, x480).
lected from a panel of mAbs on the basis of their binding to HS. This reactivity was found using crude hybridoma culture supernatants, since we have shown in previous experiments that HS reactivity is due to antibodies complexed to nuclear antigens (14) . To evaluate whether these complexed mAbs could bind to the GBM, we performed perfusion studies with complexed and noncomplexed antibody preparations and with reconstituted complexes composed of purified mAb and nucleosomes. The GBM binding was related to the composition of the antibody bound material and the reactivity of the mAb in vitro.
The purification procedures confirm our previous observations that during hybridoma culture nuclear antigens become bound to the mAbs, since we could identify core histones and DNA in the complex bound to the mAb after isolation under physiological conditions. Purification The in vitro analysis of the antigen reactivity of complexed and noncomplexed mAb indicates that binding of nucleosomal material can strongly influence the displayed specificity. In general the Farr assay is regarded as the most appropriate test to detect high avidity anti-dsDNA antibodies (22) . However, our results show that Farr positivity can be the result of binding of complexes composed of nucleosomal material and anti-nucleosome antibodies, since effective removal of these nuclear antigens leads to disappearance of the binding in the Farr assay. This Farr reactivity seems to be the result of the presence of histones within the nucleosomal particle, which is conceivable because of the DNA binding properties of these proteins. One' could argue that this phenomenon is a peculiar characteristic of these mAbs. However, preliminary data (unpublished observations) indicate that this is also true for polyclonal auto-antibodies from SLE patients. These observations however, do not reduce the usefulness of the Farr assay in the follow-up of SLE patients, since Farr positivity might be due to the presence in the circulation of auto-antibodies complexed to nucleosomes which we regard as potentially nephritogenic. Furthermore, these observations might explain why Farr positivity is associated with onset and/or exacerbation of lupus nephritis (4) and with anti-HS reactivity in SLE patients (31, 32) .
The in vitro analysis shows in addition that anti-DNA reactivity both in the Farr assay and in the ELISA and anti-histone reactivity can be a feature of antibodies primarily directed against (neo-) epitopes expressed on nucleosomes. The presence of anti-nucleosomal antibodies in SLE has been described before (33) (34) (35) . In addition, mAbs derived from lupus mice have been described which showed a much higher reactivity towards histone-DNA complexes, than to histones or DNA alone (36, 37) , and recently Losman et al described a mAb which only reacted with the intact nucleosome and not with any of the subnucleosomal particles (38) . This reactivity is similar to what we observed with purified mAbs No. 2 and 32 which also react with a neo-epitope on the intact nucleosome. The reactivity of purified mAb No. 34 is somewhat different, since it still reacted in non-complexed form with histones. From these data it is tempting to speculate that the epitope This mAb recognizes within the nucleosomes is different from that recognized by mAbs No. 2 and 32, since these became negative in the histone ELISA once purified. Our observations support the possibility that antinucleosomal autoantibodies might be present much more frequent in SLE than we appreciate today. This is further underlined by the recent report that nucleosomes are a major immunogen for pathogenic auto-antibody inducing T-helper cells (39) .
When we tested the various mAb preparation for their capacity to bind to the GBM, we found that the mAbs complexed to nucleosomal antigens (mAbs No. 2, 32 and 34) did bind to the GBM, while the noncomplexed, pure mAbs did not bind at all. To exclude that additional components from the culture supernatants copurified with the nucleosomal material are responsible for this binding, we prepared nucleosome-antibody complexes by reconstituting pure noncomplexed mAb (procedure III) with highly purified nucleosomes and again saw binding to the GBM. The observation that non-complexed mAb did not bind to the GBM does not support a direct binding to intrinsic constituents as has been suggested before (8, 40, 41) . When we analyzed the composition of the nucleosomal material which could mediate the binding of mAb to the GBM, we found that the presence of histones was critical. Furthermore, a reduction of the amount of DNA within the nucleosome enhanced this binding. This observation raises the possibility that partial digestion of the nucleosome by DNase enhances the nephritogenic potential of anti-nuclear antibodies complexed to nucleosomes. The involvement of histones in lupus nephritis is substantiated by the recent demonstration of histone deposits in both human and murine lupus nephritis (17, 18, 42) . The GBM binding of the complexes containing nucleosomal material used in the present study was different from the binding that we observed previously after subsequent perfusion of histones, DNA and anti-DNA. In our present study we found a localization throughout the whole width of the GBM and hardly any binding to endothelial or mesangial cells, whereas in our previous experiments (15) the majority of the binding occurred to endothelial cells and the lamina rara interna of the GBM. The fact that C3 deposition is induced suggests the nephritogenic potential of this binding. Our heparinase perfusion experiments show that HS is an important target for this nucleosome mediated antibody binding, but also that it is not the only anionic ligand within the GBM. Additional studies are needed to delineate further these other binding moieties. It is tempting to speculate that this nucleosome binding to HS is the explanation for our recent observation that in human (43) as well as in murine lupus nephritis (44) the HS staining in the GBM, as assessed by an anti-HS mAb, has almost completely disappeared, moreover since nucleosomes were able to inhibit the binding of this anti-HS mAb to HS in vitro.
In summary, we found that nucleosomal material can mediate the binding of antibodies to the GBM and that complexes composed of nucleosomal antigens and anti-nucleosome antibodies may show anti-DNA reactivity, even in a Farr-type assay which previously was thought to specifically detect high avidity antibodies to DNA only. Binding of these nucleosome containing complexes to the GBM, might be a first step, leading to lupus nephritis.
